Achilles Therapeutics plc
(NASDAQ: ACHL)
|
5:30 PM UTC, 07/03/24 | |||
---|---|---|---|---|
Last: $0.81 | Change: -0.02 | %Change: -2.81% | Volume: 33,827 |
Open: | $ 0.83 | Volume: | 33,827 | |
---|---|---|---|---|
High: | $ 0.83 | Yield(%) | 0.00 | |
Low: | $ 0.80 | P/E Ratio (ttm): | n/a | |
Dividend ($): | n/a | Market Cap ($): | 34.10M | |
EPS ($) | -1.31 | Shares Out: | 41.09M |
% Price Change (last 4 weeks): | -7.37 |
---|---|
% Price Change (last 13 weeks): | -29.94 |
% Price Change (last 26 weeks): | -4.39 |
% Price Change (last 52 weeks): | -11.31 |
% Price Change (year to date): | -6.64 |
Return on Equity (%): | -41.21 |
---|---|
Return on Assets (%): | -36.63 |
Return on Invested Capital (%): | -28.91 |
Gross Profit Margin (%): | n/a |
---|---|
Net Profit Margin (%): | n/a |
Operating Profit Margin (%): | 0.00 |
|
|
50-day Moving Average: | $0.87 |
---|---|
200-day Moving Average: | $0.93 |
Avg. Daily Vol. (last 50 days): | 115,950 |
Avg. Daily Vol. (last 200 days): | 328,170 |
52-wk high: | $1.76 |
52-wk low: | $0.74 |
Bid: | $0.80 |
Ask: | $0.82 |
Achilles Therapeutics Plc is a biopharmaceutical company engaged in developing transformative precision T-cell therapies to treat multiple types of solid tumors. It focuses on researching, developing and commercializing potentially novel cancer immunotherapies targeting clonal neoantigens. The company was founded by Karl Peggs, Sergio Quezada, Mark Lowdell and Charles Swanton in November 2020 and is headquartered in London, the United Kingdom.
|
Achilles Therapeutics plc
245 Hammersmith Road London GL W6 8PW Phone: 44.20.8154.4600 Fax: n/a http://www.achillestx.com |
Earnings (1year) ($): | n/a |
---|---|
Annual Dividend ($): | 0.00 |
Current P/E Ratio (ttm): | n/a |
Book Value ($): | 3.47 |
Cash Flow ($): | -1.59 |
Price/Earnings (x): | n/a |
---|---|
Price/Sales (x): | n/a |
Price/Book (x): | 0.26 |
Price/Cash Flow (x): | n/a |
Quick Ratio (x): | 8.57 |
---|---|
Current Ratio (x): | 8.57 |
LT Debt/Equity (x): | 0.76 |
Total Debt/Equity (x): | 3.24 |